Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.43 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 6/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | PNP | P00491 | 1/20 | 0.41 |
| ▸ | CDK1 | P06493 | 5/20 | 0.40 |
| ▸ | CCNB1 | P14635 | 5/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.40 |
| ▸ | CCNA1 | P78396 | 5/20 | 0.40 |
| ▸ | XDH | P47989 | 2/20 | 0.38 |
| ▸ | PI4KA | P42356 | 2/20 | 0.38 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.38 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.38 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20867 | 0.79 | ATAD2 (0.53) | PDPK1GDAHRH4DPP4PNP | |
| Water SCHEMBL27738785 | 0.78 | ADORA2A (0.54) | PDPK1GDAHRH4DPP4PNP | |
| Hydrochloric Acid SCHEMBL27339406 | 0.78 | ATAD2 (0.51) | PDPK1GDAHRH4DPP4PNP | |
| SCHEMBL27602647 | 0.76 | ATAD2 (0.49) | PDPK1GDAHRH4DPP4PNP | |
| SCHEMBL28385765 | 0.73 | DPP4 (0.41) | PDPK1GDAHRH4MAP3K5CDK2 | |
| SCHEMBL27752224 | 0.73 | CYP2C19 (0.43) | PDPK1GDAHRH4MAP3K5CDK2 | |
| SCHEMBL2118529 | 0.72 | ALDH1A1 (0.36) | XDHLMNAADORA3USP2ALDH1A1 | |
| Acetic Acid SCHEMBL1404482 | 0.72 | MGMT (0.43) | GDACDK2DPP4PNPCDK1 | |
| Thiophene SCHEMBL27638390 | 0.71 | ATAD2 (0.44) | PDPK1GDAHRH4DPP4PNP | |
| SCHEMBL9705493 | 0.70 | CDK2 (0.39) | PDPK1GDACDK2DPP4PNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 319 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026106695-A1 | TARGETED NANOPARTICLES ENCAPSULATING WATER-SOLUBLE THERAPEUTICS, METHODS OF PRODUCTION, AND USE | OPTIMEOS LIFE SCIENCES, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| WO-2026103877-A1 | LIPID COMPOUND AND LIPID NANOPARTICLE COMPOSITION | 中生复诺健生物科技(上海)有限公司 | 2026-05-21 | — | — | WO | disclosed |
| WO-2026098357-A1 | FREEZE-DRIED NUCLEIC ACID-LOADED LIPID NANOPARTICLE AND RECONSTITUTION METHOD THEREOF | KUDO BIOTECHNOLOGY, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20260130987-A1 | VACCINATION AGAINST PNEUMOCCOCAL AND COVID-19 INFECTIONS | PFIZER INC. (US) | 2026-05-14 | — | — | US | disclosed |
| WO-2026088119-A1 | LIPIDATED TLR7/8 MODULATORS AS ADJUVANTS AND USES THEREOF | PFIZER INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260109977-A1 | MODIFIED RNA FOR INCREASING PROTEIN EXPRESSION | TRILINK BIOTECHNOLOGIES, LLC (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4728076-A1 | METHOD FOR STABILIZING RNA | Pfizer Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4720094-A1 | MUTATED FRAGMENT OF VZV GLYCOPROTEIN E | Suzhou Abogen Biosciences Co., Ltd. (CN) | 2026-04-08 | — | — | EP | disclosed |
| US-12594242-B2 | Lipid compounds and lipid nanoparticle compositions | Suzhou Abogen Biosciences Co., Ltd. (CN) | 2026-04-07 | — | — | US | disclosed |
| US-20260078082-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-20090029399-A1 | METHOD FOR RAPID DETERMINATION OF THIOPURINE METHYLTRANSFERASE ACTIVITY | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH, A MINNESOTA CORPORATION | 2009-01-29 | — | — | US | disclosed |
| US-7452689-B2 | Method for rapid determination of thiopurine methyltransferase activity | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2008-11-18 | — | — | US | disclosed |
| US-20060263840-A1 | Method for rapid determination of thiopurine methyltransferase activity | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH , A MINNESOTA CORPORATION | 2006-11-23 | — | — | US | disclosed |
| US-20040047845-A1 | Methods and compositions for diagnosis and treatment of cancer based on the transcription factor ets2 | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT | 2004-03-11 | — | — | US | disclosed |
| EP-1133575-A4 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF CANCER BASED ON THE TRANSCRIPTION FACTOR ETS2 | MUSC FOUND FOR RES DEV (US) | 2003-08-13 | — | — | EP | disclosed |
| US-20020081601-A1 | Methods and compositions for diagnosis and treatment of cancer based on the transcription factor ets2 | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT. | 2002-06-27 | — | — | US | disclosed |
| EP-1133575-A2 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF CANCER BASED ON THE TRANSCRIPTION FACTOR ETS2 | MUSC Foundation For Research Development (US) | 2001-09-19 | — | — | EP | disclosed |
| WO-2000042214-A1 | PHOSPHATE RELEASE ENZYME ASSAY | PANTHERIX LTD. (GB) | 2000-07-20 | — | — | WO | disclosed |
| WO-2000030590-A2 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF CANCER BASED ON THE TRANSCRIPTION FACTOR ETS2 | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2000-06-02 | — | — | WO | disclosed |
| US-5652359-A | Oligonucleotides containing n-methyl thiolated bases having antiviral activity | EPOCH PHARMACEUTICALS, INC. (US) | 1997-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109977-A1 | MODIFIED RNA FOR INCREASING PROTEIN EXPRESSION | RNGTT, RNMT, UPF1 | PDPK1 4714/4885GDA 1345/4885HRH4 4870/4885 |
| US-20260130987-A1 | VACCINATION AGAINST PNEUMOCCOCAL AND COVID-19 INFECTIONS | SARS1, CD14, PYCARD | PDPK1 1692/4885GDA 4245/4885HRH4 4318/4885 |
| US-12594242-B2 | Lipid compounds and lipid nanoparticle compositions | NPC1, NPC1L1, PLIN3 | PDPK1 2259/4885GDA 3402/4885HRH4 1861/4885 |
| US-20260078082-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | PHOSPHO1, LIPC, SDCBP | PDPK1 799/4885GDA 3996/4885HRH4 2788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.